Experimental Hematology
Volume 38, Issue 11 , Pages 1066-1073 , November 2010

Streptamer-based selection of WT1-specific CD8+ T cells for specific donor lymphocyte infusions

  • Xinchao Wang

      Affiliations

    • Department of Internal Medicine III, University of Rostock, Rostock, Germany
    • Department of Hematology and Oncology, Zhongda Hospital, Southeast University Medical School, Nanjing, P.R. China
    • Department of Oncology, The Fourth Center Clinical College of Tianjin Medical University, Tianjin, P.R. China
    • ,
  • Anita Schmitt

      Affiliations

    • Department of Internal Medicine III, University of Rostock, Rostock, Germany
    • ,
  • Baoan Chen

      Affiliations

    • Department of Hematology and Oncology, Zhongda Hospital, Southeast University Medical School, Nanjing, P.R. China
    • ,
  • Xun Xu

      Affiliations

    • Department of Internal Medicine III, University of Rostock, Rostock, Germany
    • Department of Immunology, Jiangsu University, Zhenjiang, P.R. China
    • ,
  • Jiju Mani

      Affiliations

    • Department of Internal Medicine III, University of Rostock, Rostock, Germany
    • ,
  • Michael Linnebacher

      Affiliations

    • Department of Surgery, University of Rostock, Rostock, Germany
    • ,
  • Mathias Freund

      Affiliations

    • Department of Internal Medicine III, University of Rostock, Rostock, Germany
    • ,
  • Michael Schmitt

      Affiliations

    • Department of Internal Medicine III, University of Rostock, Rostock, Germany
    • Corresponding Author InformationOffprint requests to: Michael Schmitt, M.D., Ph.D., Clinical Stem Cell Transplantation and Immunotherapy, Department of Internal Medicine III, University of Rostock, Ernst-Heydemann-Str. 6, Rostock 18055, Germany

Received 26 December 2009 ,Revised 2 July 2010 ,Accepted 6 July 2010.

References 

  1. Haber DA, Buckler AJ, Glaser T, et al. An internal deletion within an 11p13 zinc finger gene contributes to the development of Wilms’ tumor. Cell. 1990;60:1257–1269
  2. Miwa H, Beran M, Saunders GF. Expression of the Wilms’ tumor gene (WT1) in human leukemias. Leukemia. 1992;6:405–409
  3. Ariyaratana S, Loeb DM. The role of the Wilms tumour gene (WT1) in normal and malignant haematopoiesis. Expert Rev Mol Med. 2007;14:1–17
  4. Scheibenbogen C, Letsch A, Thiel E, et al. CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. Blood. 2002;100:2132–2137
  5. Smits EL, Berneman ZN, Van Tendeloo VF. Immunotherapy of acute myeloid leukemia: current approaches. Oncologist. 2009;14:240–252
  6. Keilholz U, Letsch A, Busse A, et al. A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood. 2009;113:6541–6548
  7. Yao J, Bechter C, Wiesneth M, et al. Multimer staining of cytomegalovirus phosphoprotein 65-specific T cells for diagnosis and therapeutic purposes: a comparative study. Clin Infect Dis. 2008;46:e96–e105
  8. Neudorfer J, Schmidt B, Huster KM, et al. Reversible HLA multimers (Streptamers) for the isolation of human cytotoxic T lymphocytes functionally active against tumor- and virus-derived antigens. J Immunol Methods. 2007;320:119–131
  9. Kolb HJ. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood. 2008;112:4371–4383
  10. Guglielmi C, Arcese W, Dazzi F, et al. Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose. Blood. 2002;100:397–405
  11. Raiola AM, Van Lint MT, Valbonesi M, et al. Factors predicting response and graft-versus-host disease after donor lymphocyte infusions: a study on 593 infusions. Bone Marrow Transplant. 2003;31:687–693
  12. Weisser M, Tischer J, Schnittger S, Schoch C, Ledderose G, Kolb HJ. A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation. Haematologica. 2006;91:663–666
  13. Collins RH, Shpilberg O, Drobyski WR, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol. 1997;15:433–444
  14. Slavin S, Ackerstein A, Morecki S, Gelfand Y, Cividalli G. Immunotherapy of relapsed resistant chronic myelogenous leukemia post allogeneic bone marrow transplantation with alloantigen pulsed donor lymphocytes. Bone Marrow Transplant. 2001;28:795–798
  15. Ruggeri L, Capanni M, Casucci M, et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood. 1999;94:333–339
  16. Morecki S, Lindhofer H, Yacovlev E, Gelfand Y, Slavin S. Use of trifunctional bispecific antibodies to prevent graft versus host disease induced by allogeneic lymphocytes. Blood. 2006;107:1564–1569
  17. Call KM, Glaser T, Ito CY, et al. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms’ tumor locus. Cell. 1990;60:509–520
  18. Mundlos S, Pelletier J, Darveau A, Bachmann M, Winterpacht A, Zabel B. Nuclear localization of the protein encoded by the Wilms’ tumor gene WT1 in embryonic and adult tissues. Development. 1993;119:1329–1341
  19. Inoue K, Sugiyama H, Ogawa H, et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood. 1994;84:3071–3079
  20. Cilloni D, Renneville A, Hermitte F, et al. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study. J Clin Oncol. 2009;27:5195–5201
  21. Oji Y, Ogawa H, Tamaki H, et al. Expression of the Wilms’ tumor gene WT1 in solid tumors and its involvement in tumor cell growth. Jpn J Cancer Res. 1999;90:194–204
  22. Oka Y, Elisseeva OA, Tsuboi A, et al. Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms’ tumor gene (WT1) product. Immunogenetics. 2000;51:99–107
  23. Ohminami H, Yasukawa M, Fujita S. HLA class I-restricted lysis of leukemia cells by a CD8 (+) cytotoxic T-lymphocyte clone specific for WT1 peptide. Blood. 2000;95:286–293
  24. Weber G, Karbach J, Kuçi S, et al. WT1 peptide-specific T cells generated from peripheral blood of healthy donors: possible implications for adoptive immunotherapy after allogeneic stem cell transplantation. Leukemia. 2009;23:1634–1642
  25. Voss S, Skerra A. Mutagenesis of a flexible loop in streptavidin leads to higher affinity for the Strep-tag II peptide and improved performance in recombinant protein purification. Protein Eng. 1997;10:975–982
  26. Rezvani K, Yong AS, Savani BN, et al. Graft-versus-leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia. Blood. 2007;110:1924–1932
  27. Morita Y, Heike Y, Kawakami M, et al. Monitoring of WT1-specific cytotoxic T lymphocytes after allogeneic hematopoietic stem cell transplantation. Int J Cancer. 2006;119:1360–1367
  28. Pittet M, Rubio-Godoy V, Bioley G, et al. Alpha 3 domain mutants of peptide/MHC class I multimers allow the selective isolation of high avidity tumor-reactive CD8 T cells. J Immunol. 2003;171:1844–1849
  29. Sallusto F, Lenig D, Förster R, et al. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 1999;401:708–712

PII: S0301-472X(10)00283-3

doi: 10.1016/j.exphem.2010.07.002

Experimental Hematology
Volume 38, Issue 11 , Pages 1066-1073 , November 2010

Article Tools

* Image Usage & Resolution